Twenty years on: the impact of fragments on drug discovery

Nat Rev Drug Discov. 2016 Sep;15(9):605-619. doi: 10.1038/nrd.2016.109. Epub 2016 Jul 15.


After 20 years of sometimes quiet growth, fragment-based drug discovery (FBDD) has become mainstream. More than 30 drug candidates derived from fragments have entered the clinic, with two approved and several more in advanced trials. FBDD has been widely applied in both academia and industry, as evidenced by the large number of papers from universities, non-profit research institutions, biotechnology companies and pharmaceutical companies. Moreover, FBDD draws on a diverse range of disciplines, from biochemistry and biophysics to computational and medicinal chemistry. As the promise of FBDD strategies becomes increasingly realized, now is an opportune time to draw lessons and point the way to the future. This Review briefly discusses how to design fragment libraries, how to select screening techniques and how to make the most of information gleaned from them. It also shows how concepts from FBDD have permeated and enhanced drug discovery efforts.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Computational Biology
  • Drug Discovery / trends*
  • High-Throughput Screening Assays
  • Humans
  • Peptide Fragments / pharmacology*
  • Peptide Library
  • Protein Conformation
  • Small Molecule Libraries


  • Peptide Fragments
  • Peptide Library
  • Small Molecule Libraries